Patient Guide: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 13 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06906822
Status: 🟢 Enrolling Now
Condition: Melanoma
Phase: PHASE2

Where You Can Participate

This study is available at 13 locations across the country.

Top locations include:
  • • A Coruña, A Coruña
  • • Badalona, Barcelona
  • • Barcelona, Barcelona
  • • And 10 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients - Join Clinical Trial NCTNCT06906822

How to Join This Clinical Trial - NCTNCT06906822

Learn how to participate in this PHASE2 trial studying an investigational therapy for Melanoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Melanoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Melanoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06906822 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 13 locations. Find a study site near you:

Clinical Research Site

A Coruña, A Coruña 15006 - Spain

Status: RECRUITING

Clinical Research Site

Badalona, Barcelona 08916 - Spain

Status: RECRUITING

Clinical Research Site

Barcelona, Barcelona 08028 - Spain

Status: NOT_YET_RECRUITING

Clinical Research Site

Barcelona, Barcelona 08035 - Spain

Status: RECRUITING

Clinical Research Site

Barcelona, Barcelona 08036 - Spain

Status: RECRUITING

Clinical Research Site

Santander, Cantabria 39008 - Spain

Status: RECRUITING

Clinical Research Site

Madrid, Madrid 28034 - Spain

Status: RECRUITING

Clinical Research Site

Madrid, Madrid 28041 - Spain

Status: RECRUITING

Clinical Research Site

Madrid, Madrid 28046 - Spain

Status: RECRUITING

Clinical Research Site

Murcia, Murcia 30120 - Spain

Status: RECRUITING

And 3 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Melanoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships